By Spondylitis Association of America
A Phase 3 clinical trial is now recruiting patients over the age of 18 with active ankylosing spondylitis (AS) to participate.
The purpose of the trial, titled, “Efficacy and Safety of Tofacitinib in Subjects with Active Ankylosing Spondylitis (AS)” is to determine if Tofacitinib is safe and effective in subjects with active ankylosing spondylitis
By Liz Maines
Uggh… the holidays and spondyloarthritis …what a mixed bag. Living with a chronic illness such as this, puts us in the unique position of frequently assessing our energy level. The holiday hustle and bustle can challenge us both emotionally and physically. I wanted to share a few tips I have learned that may help you survive and maybe even enjoy the holiday season.
Helpful Hints is a recurring feature, aimed at sharing our community’s knowledge and experiences. In this second installment, we asked our online community to share their recommendations for mattresses and pillows that have been beneficial for their chronic pain. We share a sample of responses with our thanks. We hope you find them helpful!
A new phase 3 clinical trial tested the efficacy and safety of the IL-17 inhibitor ixekizumab (brand name Taltz) in a population of ankylosing spondylitis (AS) patients who did not improve with TNF inhibitor (TNFi) treatment. Studies report that roughly 30 percent of those with AS don’t see enough improvement with their TNFi medications to continue treatment.
On October 20th, 2018 the Spondylitis Association of America hosted a free Spondylitis Educational Seminar in Chicago, IL. Our speakers for the day were Rheumatologist Dr. Muhammad Asim Khan, MD, MACP, FRCP and Registered Dietician Lara Rondinelli-Hamilton, RD, LDN, CDE.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.